1-4 of 4
Steve A. Schey
Close
Sort by
Journal Articles

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

Matthew J. Streetly, Lenushka Maharaj, Simon Joel, Steve A. Schey, John G. Gribben, Finbarr E. Cotter
Journal: Blood
Blood (2010) 115 (19): 3939–3948.
https://doi.org/10.1182/blood-2009-10-251660
Published: 2010
Journal Articles

The Thalidomide Analogue (Actimid) Induces T-Cell Activation at Day 28 in Patients with Relapsed Refractory Myeloma but Does Not Correlate with Improved Outcome.

Gulrukh Ahsan, MSc, Mathew Streetly, MD, Paul A. Fields, MD, PhD, Auther R. Bradwell, PhD, Steve A. Schey, MD, Majid Kazmi, MD
Journal: Blood
Blood (2005) 106 (11): 3473.
https://doi.org/10.1182/blood.V106.11.3473.3473
Published: 2005
Journal Articles

Population-Based Survey of Adult Myeloid Malignancies (MDS, CMPDs and AML) in 2,112 Patients from a Defined UK Geographical Area.

Karen J. Phekoo, PhD, Mike A. Richards, MD, Henrik Moller, DM, Steve A. Schey, MD, on Behalf of South Thames Haematology Committee
Journal: Blood
Blood (2005) 106 (11): 5564.
https://doi.org/10.1182/blood.V106.11.5564.5564
Published: 2005
Journal Articles

Alternate Day Actimid™ (CC-4047) Is Well Tolerated and Is Active When Used to Treat Relapsed/Refractory Myeloma.

Matthew Streetly, BM, BS, Kylie Gyertson, Majid Kazmi, Jerome Zeldis, Steve A. Schey
Journal: Blood
Blood (2004) 104 (11): 332.
https://doi.org/10.1182/blood.V104.11.332.332
Published: 2004